Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar Ranibizumab

NCT07520045 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Diabetic Retinopathy (DR)
Diabetic Macular Edema (DME)

Interventions

DRUG: Faricimab
DRUG: Biosimilar ranibizumab

Sponsor

Osijek University Hospital